Sonoma Pharmaceu Stock Price, News & Analysis

Sonoma Pharmaceuticals has launched Podiacyn, an all-natural foot care product designed for over-the-counter use in the U.S. This product aims to manage foot odors, infections, and irritations while enhancing the body’s natural healing process. Podiacyn is clinically proven to eliminate bacteria and fungi, and its formulation is free of dyes, fragrances, and preservatives. The new product is available for consumers directly through their website and through third-party distributors. CEO Amy Trombly highlighted the opportunity in the growing global footcare market, which is expected to reach $5.4 billion by 2028, up from $3.7 billion in 2021. The launch reflects Sonoma's strategy to leverage its patented Microcyn technology, promoting foot health and hygiene.

Sonoma Pharmaceuticals (Nasdaq:SNOA) will showcase its Microcyn® technology-based products at the CPHI North America Conference in Philadelphia from April 25-27, 2023. The company aims to expand its distribution network in North America by attracting new partners and distributors. Attending this conference provides Sonoma with an opportunity to connect with pharmaceutical leaders and further grow its business through diversification of its product offerings. The company specializes in stabilized hypochlorous acid products for various applications, including wound and animal care, marketed in 55 countries.

Sonoma Pharmaceuticals (Nasdaq:SNOA) and MicroSafe Group announced that their Nanocyn hospital-grade disinfectant has received new claims from the U.S. EPA effective against harmful pathogens including MRSA, Salmonella, and Norovirus. Additionally, Nanocyn earned the Green Seal Certification, highlighting its commitment to environmental health and sustainability. This disinfectant is already EPA-approved for various applications in healthcare and beyond. Expectations are set for commercialization by summer 2023. Both companies view these advancements as significant for enhancing product reliability and environmental responsibility.

Sonoma Pharmaceuticals (NASDAQ:SNOA) reported a cash burn of $717,000 for Q3 2022, significantly down from $2,235,000 in the previous quarter. Revenues remained flat at $2.9 million for the quarter, with a notable 51% increase in European sales. However, U.S. consumer product sales declined due to broader economic challenges. Operating expenses rose to $2.7 million, a 23% increase year-over-year, primarily from facility closures and one-time expenses. The net loss before taxes for the quarter was $1.9 million, up from $0.9 million last year. Overall, Sonoma is positioning for growth through new product launches and increased international partnerships.

Sonoma Pharmaceuticals (Nasdaq:SNOA) has established a distribution agreement with Daewoong Pharmaceutical, one of South Korea's largest pharmaceutical companies, to market and distribute Primocyn Skin Solution. This partnership aims to leverage Daewoong's expertise to enhance sales of Primocyn products, which utilize Sonoma's patented Microcyn technology. Notably, Daewoong generates over $1 billion in annual revenues. The collaboration is expected to open new sales channels for Sonoma's products in South Korea, where Primocyn has a history of sales.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) announced that its Microcyn^® Rx products have secured a Distribution and Pricing Agreement (DAPA) with the Defense Logistics Agency (DLA) through its partner, EMC Pharma. This DAPA allows EMC Pharma to distribute Microcyn^® products, which include wound care and dermatology items, to federal customers such as VA hospitals and the Department of Defense. The partnership enables Sonoma to tap into the U.S. government's extensive purchasing power, expanding its market presence significantly.

Sonoma Pharmaceuticals has launched a new line of office dispense products for skin care professionals, including Regenacyn Plus, Reliefacyn Plus, and Rejuvacyn Plus. These products are designed to enhance patient outcomes and convenience by allowing clients to purchase prescription-strength products directly from their dermatologists and medical spas. Sonoma's products utilize patented Microcyn technology, known for its healing and infection-fighting properties. This initiative aims to tap into the growing aesthetic procedure market while providing added revenue streams for practices.

Sonoma Pharmaceuticals (SNOA) reported a mixed financial performance for Q2 and six months ended September 30, 2022. Revenues for Q2 were $3.3 million, a decrease of 11% from $3.7 million year-over-year, while international sales grew by 18%. Gross profit improved to 40% from 33% due to increased production efficiency. Operating loss decreased by 24%, reaching $0.9 million. The total net loss before taxes for six months was $1.9 million, up from $1.2 million last year. The company is optimistic about future profitability driven by a successful transition to a distribution model.

Sonoma Pharmaceuticals (Nasdaq:SNOA) announced the launch of two dermatological products: Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Rejuvacyn Advanced Skin Repair Cooling Mist for over-the-counter use in the U.S. Reliefacyn targets symptoms of eczema and skin irritations, while Rejuvacyn aids recovery after cosmetic procedures. Both products emphasize natural formulation and efficacy in healing. CEO Amy Trombly highlighted the expansion of their consumer-focused product line to address common skin conditions. Products are available via the company’s website and distributors.